U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 11 - 20 of 3,321 results

Status:
US Approved Rx (2024)
First approved in 2024

Class (Stereo):
CHEMICAL (ACHIRAL)



Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. GFT505 has an active metabolite, GFT1007, and both have potent agonist activity for PPAR-a and to a lesser extent...
Status:
US Approved Rx (2024)
First approved in 2024

Class (Stereo):
CHEMICAL (ABSOLUTE)



Arimoclomol citrate is an experimental drug developed by a biopharmaceutical company CytRx Corporation. In 2011 the worldwide rights to arimoclomol were bought by Danish biotech company Orphazyme ApS. The European Medicines Agency (EMA) and U.S. Food...
Status:
US Approved Rx (2024)
First approved in 2024

Class (Stereo):
CHEMICAL (ABSOLUTE)


MBX-8025 (Seladelpar) is an agonist of peroxisome proliferator-activated receptor delta. MBX-8025 improves insulin sensitivity and reverses dyslipidemia and hepatic storage of lipotoxic lipids to improve nonalcoholic steatohepatitis pathology in athe...
Status:
US Approved Rx (2024)
First approved in 2024

Class (Stereo):
CHEMICAL (ABSOLUTE)



AMD-070 is a small molecule drug candidate that belongs to a new investigational class of anti-HIV drugs known as entry (fusion) inhibitors. Approximately 76% of HIV-patients with measurable viral load are infected with a strain of virus that is resi...
Status:
US Approved Rx (2024)
First approved in 2024

Class (Stereo):
CHEMICAL (MIXED)

Status:
US Approved Rx (2023)
First approved in 2023

Class (Stereo):
CHEMICAL (ACHIRAL)



Momelotinib (CYT387) is an ATP-competitive small molecule that potently inhibits JAK1/JAK2 kinases. Momelotinib is developing by Gilead Sciences for the oral treatment of pancreatic and non-small cell lung cancers, and myeloproliferative disorders (i...
Status:
US Approved Rx (2023)
First approved in 2023

Class (Stereo):
CHEMICAL (ACHIRAL)


Taurolidine [bis(1,1-dioxoperhydro-1,2,4-thiadiazinyl-4)-methane (TRD)], a product derived from the aminosulfoacid taurin, was first described as an anti-bacterial substance. Taurolidine is a small dimeric molecule with molecular weight 284. It compr...
Status:
US Approved Rx (2023)
First approved in 2023

Class (Stereo):
CHEMICAL (ABSOLUTE)

BioLineRx Ltd has developed BL-8040, a short peptide for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation. BL-8040 acts as CXCR4 antagonist. CXCR4 is a chemokine receptor that i...
Status:
US Approved Rx (2023)
First approved in 2023

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
US Approved Rx (2023)
First approved in 2023

Class (Stereo):
CHEMICAL (ABSOLUTE)



Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell prolifer...

Showing 11 - 20 of 3,321 results